Stanfield et. al (1999) Outline: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
No edit summary
Line 27: Line 27:
=Results and discussion=
=Results and discussion=
==Structure determination and refinement==
==Structure determination and refinement==
*Fab 58.2 structures 1 linear & two hydrazone-linked cyclic peptides (respectively 2.0A & 2.8A).
*Isomorphous structures were determined for crystals of the two Fab-cyclic peptide complexes. Due to single a.a. difference in their peptides.
*Fab molecules identified as L (light chain) and H(heavy chain). BH10 isolate sequence --> how peptides are numbered along with Peptide chain identifier.
**After P316, two a.a. insert interrupts numbering system. 
**Fab 58.2-Aib142 have Fab residues L1-L212, H1-H230 and P313-P325 peptide residues.
**Fab 58.2 His-loop -- L1-L212, H1-H230 fab residues w/ hydrazone linker
**Fab 58.2 Ser-loop -- L1-L211, H1-H230 fab residues w/ cyclic peptide, no hydrazone linker.
*Fab-Aib142 peptide complex structure - 89%  residues in favored positions (3 in disallowed regions).
**Disallowed residues -- 2 found in the constant heavy chain in a disordered loop and 1 residue (Ala L51) that is i+2 in distorted type I turn
*2.8 A resolution determined 2 fab-cyclic peptide structures, only differ at 1 residue in peptide.
**His loop complex - 81% residues found in favored positions (w/ 3 in disallowed regions)
**Ser loop complex - 87% residues found in favored positions (w/ 5 in disallowed regions)

Revision as of 16:21, 16 October 2011

Introduction

  • HIV-1's exterior membrand is embedded with protein copes of gp120 and gp41. Viral cell entry --> gp120 binds to CD4 and another co receptor, gp41 then fusions the viral --> target cell membranes.
  • CXCR4 and CCR5 serve as secondary viral receptors to T-tropic and M-tropic cells.
  • Disulfide linked loop is the V3 domain of gp120, 40 amino acids have high degree of sequence diversity. V3=major immunogenic site of virus (termed principal neutralizing determinant.)
  • V3 loop exposure varies. Increases when CD4-gp120 interaction. More sensitive to neutralize proteases and antibodies. T-tropic V3 seq. --> more basic charge than M-tropic, due to either side of GPGR tip being positivley charged.
  • Examined 245 diff. HIV-1 V-3 loops
    • Some positions of aa are highly variable in aa composition.
    • Near tip of loop --> highly conserved
      • Suggests key fn. and structural role in virus infectivity.
  • Disease progression = conversion of primary M-tropic to T-tropic strains. Knowing about conformational loops could help explain changes that take place and coreceptor usage when leading to disease progression.
  • Antibodies were let against 40a.a V3 peptide RP70; showed that by preventing viral-cell membrane fusion, it neutralized the virus.
    • Previously thought that these antibodies do not interfere with CD4 binding. Using intact viral gp120 particles in recent studies, show that V3 neutralizing antibodies could prevent HIV-1 binding to CD4+ human cells.
  • 50.1 & 59.1 antibody Fab fragments in correlation with V3 peptides. 50.1 - highly specific for MN viral strand. 59.1 - neutralize T-tropic strongly and MN weakly.
  • 8a.a. residues from 50.1 were ordered in antibody combining site. Residues were extended beta conformation, two lle residues found in hydrophobic pockets, GPG starting to turn.
    • Torsion angle between epsilon region for Gly residue, torsion angle for PG were type II beta turn.
  • 59.1 - 10a.a. residues visible. Five had structural counterparts with 50.1 along with similar mainchain torsion angles.
  • Around GPGR, type II beta turn had double bend with type I turn for residues RAFY and GRAF. Arg side chain buried deep in negatively charged pocket.
  • Single tight turn around GPGR, found now that it is a much broader double turn. --> double bend around GRAFY & around GPGR, had a single tight turn.
  • Ala residue - alpha helical torsion angles of -60 & -45. Similar to Aib.
    • Replace Ala for Aib --> constrain the peptide.
  • X-ray structure --> Aib had no sig. peptide conformational changes. Aib not needed for crystallization or binding.
  • Restrict conformation of V3 peptides - incorporating hydrazone bond using synthetic hydrogen.
  • Fab 58.2 - broadly neutralizing & highly potent antibody
    • Neutralizes M-Tropic and T-Tropic viral strains
    • Structure = two cyclic constrained peptides and Aib-containing peptide

Results and discussion

Structure determination and refinement

  • Fab 58.2 structures 1 linear & two hydrazone-linked cyclic peptides (respectively 2.0A & 2.8A).
  • Isomorphous structures were determined for crystals of the two Fab-cyclic peptide complexes. Due to single a.a. difference in their peptides.
  • Fab molecules identified as L (light chain) and H(heavy chain). BH10 isolate sequence --> how peptides are numbered along with Peptide chain identifier.
    • After P316, two a.a. insert interrupts numbering system.
    • Fab 58.2-Aib142 have Fab residues L1-L212, H1-H230 and P313-P325 peptide residues.
    • Fab 58.2 His-loop -- L1-L212, H1-H230 fab residues w/ hydrazone linker
    • Fab 58.2 Ser-loop -- L1-L211, H1-H230 fab residues w/ cyclic peptide, no hydrazone linker.
  • Fab-Aib142 peptide complex structure - 89% residues in favored positions (3 in disallowed regions).
    • Disallowed residues -- 2 found in the constant heavy chain in a disordered loop and 1 residue (Ala L51) that is i+2 in distorted type I turn
  • 2.8 A resolution determined 2 fab-cyclic peptide structures, only differ at 1 residue in peptide.
    • His loop complex - 81% residues found in favored positions (w/ 3 in disallowed regions)
    • Ser loop complex - 87% residues found in favored positions (w/ 5 in disallowed regions)